Abstract:Yixue Hu, 1 Dongna Wang, 2 Tianyu Zhang, 2 Meng Lei, 3 Yingnan Luo, 2 Zhimeng Chen, 3 Yuting Li, 2 Dandan Duan, 2 Liefeng Zhang, 1 Yongqiang Zhu 1, 2 1 College of Life Science, Nanjing Normal University, Nanjing, People's Republic of China; 2 School of Food and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, People's Republic of China; 3 College of Science, Nanjing Forestry University, Nanjing, People's Republic of China Correspondence: Liefeng Zhang; Yongqiang Zhu, College of Life Science, Nanjing Normal University, No. 1 Wenyuan Road, Qixia District, Nanjing, 210023, People's Republic of China, Tel/Fax +86-25-85898184; +86-25-85891591, Email ; Introduction: Tumor hypoxia and invasion present significant challenges for the efficacy of photodynamic therapy (PDT) in triple-negative breast cancer (TNBC). This study developed a mitochondrial targeting strategy that combined PDT and gene therapy to promote each other and address the challenges. Methods: The positively charged amphiphilic material triphenylphosphine-tocopherol polyethylene glycol succinate (TPP-TPGS, TPS) and the photosensitizer chloride e6 (Ce6) formed TPS@Ce6 nanoparticles (NPs) by hydrophobic interaction. They electrostatically condensed microRNA-34a (miR-34a) to form stable TPS@Ce6/miRNA NPs. Results: Firstly, Ce6 disrupted the lysosomal membrane, followed by successful delivery of miR-34a by TPS@Ce6/miRNA NPs. Meanwhile, miR-34a reduced ROS depletion and further enhanced the effectiveness of PDT. Consequently, the mutual promotion between PDT and gene therapy led to enhanced anti-tumor effects. Furthermore, the TPS@Ce6/miRNA NPs promoted apoptosis by down-regulating Caspase-3 and inhibited tumor cell migration and invasion by down-regulating N-Cadherin. In addition, in vitro and in vivo experiments demonstrated that the TPS@Ce6/miRNA NPs achieved excellent anti-tumor effects. These findings highlighted the enhanced anticancer effects and reduced migration of tumor cells through the synergistic effects of PDT and gene therapy. Conclusion: Taken together, the targeted co-delivery of Ce6 and miR-34a will facilitate the application of photodynamic and genic nanomedicine in the treatment of aggressive tumors, particularly TNBC. Keywords: photodynamic therapy, gene therapy, hypoxia, invasion, mitochondrial target, triple-negative breast cancer Graphical Breast cancer remains the most prevalent solid tumor among women and ranks as the second leading cause of cancer-related death in women. 1 Triple-negative breast cancer (TNBC) is particularly heterogeneous, accounting for about 10%-15% of diagnosed breast cancer cases, and is associated with a poor prognosis and aggressive behavior. 2 Notably, some studies have indicated that breast cancer-related deaths often result from the metastasis of cancer cells to vital organs, with TNBC showing a higher propensity for brain and lung metastases. 3–5 Given the aggressive nature and high incidence of TNBC, there arises an urgent need to develop novel therapeutic strategies specific to this subtype. 6 Hence, the development of novel therapies for TNBC is of utmost importance. Photodynamic therapy (PDT) is a promising treatment that utilizes non-toxic photosensitizers to transfer light energy to oxygen, resulting in the generation of reactive oxygen species (ROS) that can interact with biomolecules and induce cancer cell death. 7 PDT offers advantages such as minimal invasiveness, and broad applicability. 8,9 Furthermore, it has been suggested that PDT may inhibit the metastatic potential of cancer cells. 10 Therefore, PDT holds the potential as a conservative treatment of early or refractory breast cancer. 11 However, the presence of hypoxia in the tumor microenvironment can diminish the effectiveness of photodynamic therapy. 12 Cancer cells surviving PDT under hypoxic conditions may exhibit increased malignancy and a higher likelihood of local recurrence, metastasis, and regeneration of solid tumors. 12,13 Additionally, PDT is not suitable for patients with disseminated cancer, as current technology does not allow for proper whole-body irradiation. 14 Given the limitations of conventional PDT modalities, ongoing efforts are focused on improving photodynamic therapy. Initial strategies involved the use of hyperbaric oxygen therapy. 15 However, side effects such as hyperoxic epilepsy and barotrauma have hindered its clinical application. 16 Subsequently, researchers explored the use of nanoplatforms to supply oxygen directly -Abstract Truncated-

Combination of verteporfin-photodynamic therapy with 5-aza-2'-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer

The therapeutic efficacy of 5-ALA based photodynamic therapy and chemotherapy combination in triple negative breast cancer cells

Abstract 4977: Immunogenic Chemotherapy Synergize PD-1 Blockade by Enhancing Dendritic Cells Infiltration in Triple-Negative Breast Cancer (TNBC)

Combined CB2 receptor agonist and photodynamic therapy synergistically inhibit tumor growth in triple negative breast cancer

Light-inducible nanodrug-mediated photodynamic and anti-apoptotic synergy for enhanced immunotherapy in triple-negative breast cancer

Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers

Combining Photodynamic Therapy with Immunostimulatory Nanoparticles Elicits Effective Anti-Tumor Immune Responses in Preclinical Murine Models

Enhanced Anti-Tumor Efficacy through a Combination of Integrin αvβ6-Targeted Photodynamic Therapy and Immune Checkpoint Inhibition.

Dual immunostimulatory CD73 antibody-polymeric cytotoxic drug complex for triple negative breast cancer therapy

Photodynamic therapy changes tumour immunogenicity and promotes immune-checkpoint blockade response, particularly when combined with micromechanical priming

Synergistic Effects of Photodynamic Therapy and Chemotherapy: Activating the Intrinsic/extrinsic Apoptotic Pathway of Anoikis for Triple-Negative Breast Cancer Treatment

Improving Anti-Pd-l1 Therapy in Triple Negative Breast Cancer by Polymer-Enhanced Immunogenic Cell Death and CXCR4 Blockade

Chlorin Conjugates in Photodynamic Chemotherapy for Triple-Negative Breast Cancer

Enhanced systemic antitumor efficacy of PD‐1/PD‐L1 blockade with immunological response induced by photodynamic therapy

Abstract 4565: Effective Inhibition of Metastasis in Triple-Negative Breast Cancer (TNBC) Mouse Model by Combining Immunogenic Chemotherapy and Immune Checkpoint Blockade

Drug Self‐Delivery Nanocubes Enhance O2‐Economized Photodynamic‐Immunotherapy of Triple‐Negative Breast Cancer by Downregulating Wnt/β‐catenin Signaling

Metformin and oxyphotodynamic therapy as a novel treatment approach for triple-negative breast cancer.

Combined Photosensitive Gene Therapy Effective Against Triple-Negative Breast Cancer in Mice Model

Enhanced antitumor effects of BPD-MA-mediated photodynamic therapy combined with adriamycin on breast cancer in mice

Enhanced anticancer efficacy of photodynamic therapy in combination with immunotherapy

Combination of vitamin D and photodynamic therapy enhances immune responses in murine models of squamous cell skin cancer